title: Genotoxic activity of praziquantel.
abstract: Praziquantel is a synthetic drug with a remarkable activity against parasites, particularly treamatodes and cestodes. Initial genotoxicity tests used a spectrum of endpoints including tests in bacteria, yeasts, mammalian cells and Drosophila and each one gave negative results. Effects on reproductive cells of mice were negative as well. However, host mediated studies in mice and humans were contradictory and a comutagenic effect with several mutagens and carcinogens was found. Later studies, including monitoring in humans and pigs have shown that Praziquantel induces a greater frequency of hyperploid lymphocytes as well as structural chromosomal aberrations, but not in all the individuals treated. In vitro studies have demonstrated that Praziquantel can induce micronuclei in syrian hamster embryonic (SHE) cells and in lymphocytes of some individuals. The same was found about structural chromosomal aberrations. Fetal death and fetal resorption were found when Praziquantel was administered in high doses to pregnant rats between the 6th and 10th day of gestation. Due to its efficiency as a parasiticide, Praziquantel is in use in Latin-American, Asiatic, African and East-European countries where infections by trematodes and cestodes are frequent. However, the extensive use of Praziquantel in multiple reinfections, in non-infected and non-diagnosed individuals for prevention, in higher doses or repeated doses for cysticercosis treatment and in individuals exposed to environmental mutagens, in conjunction with new findings about its metabolism and genotoxic properties, make it necessary to further evaluate the potential of this drug not only to be mutagenic per se, but to contribute in the development of neoplasm.
authors.affiliation: Departamento de Genética y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, UNAM, Mexico. dorinda@servidor.unam.mx
authors.forename: R
authors.initials: R
authors.lastname: Montero
authors.forename: P
authors.initials: P
authors.lastname: Ostrosky
mesh_terms: D000818:Animals; D000980:Antiplatyhelmintic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000494:pharmacology; D002986:Clinical Trials as Topic; D006224:Cricetinae; D003551:Cysticercosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D051379:Mice; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology; D011223:Praziquantel / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D011247:Pregnancy; D051381:Rats; D012552:Schistosomiasis / Q000188:drug therapy
chemical_list: D000980:Antiplatyhelmintic Agents; D002273:Carcinogens; D009153:Mutagens; D011223:Praziquantel